PedAM
Pediatric Disease Annotations & Medicines
| mycoplasma infections | ||||
| Disease ID | 1356 |
|---|---|
| Disease | mycoplasma infections |
| Definition | Infections with species of the genus MYCOPLASMA. |
| Synonym | [x]mycoplasma infection, unspecified [x]mycoplasma infection, unspecified (disorder) disease caused by mycoplasma disease caused by mycoplasma (disorder) disease caused by mycoplasma [ambiguous] disease caused by mycoplasma, nos disease caused by mycoplasma, nos (disorder) infect mycoplasma infection by mycoplasma infection by mycoplasma, nos infection by pplo infection by pplo, nos infection, mycoplasma infections, mycoplasma mycoplasma infect mycoplasma infection mycoplasma infection (disorder) mycoplasma infections [disease/finding] mycoplasmosis mycoplasmosis (disorder) mycoplasmosis, nos |
| DOID | |
| UMLS | C0026936 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:10) C0004096 | asthma | 2 C0021359 | infertile | 2 C0035204 | respiratory disease | 2 C0035455 | rhinitis | 1 C0034069 | pulmonary fibrosis | 1 C0027059 | myocarditis | 1 C0013418 | dystocia | 1 C0014742 | erythema multiforme | 1 C0006017 | pertussis | 1 C0009763 | conjunctivitis | 1 |
| Curated Gene | Entrez_id | Symbol | Resource(Total Genes:3) |
| Inferring Gene | (Waiting for update.) |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 1356 |
|---|---|
| Disease | mycoplasma infections |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:11) HP:0002099 | Asthma | 2 HP:0002664 | Neoplasia | 1 HP:0012819 | Myocarditis | 1 HP:0030731 | Carcinoma | 1 HP:0000365 | Hearing impairment | 1 HP:0000407 | sensorineural hearing loss | 1 HP:0010783 | Erythema | 1 HP:0000509 | Conjunctivitis | 1 HP:0002098 | Respiratory distress | 1 HP:0012384 | Nasal inflammation | 1 HP:0002206 | Pulmonary fibrosis | 1 |
| Disease ID | 1356 |
|---|---|
| Disease | mycoplasma infections |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:1) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:4) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0026936 | chlorpromazine | D002746 | 50-53-3 | mycoplasma infections | MESH:D009175 | therapeutic | 10773494 | ||
| C0026936 | ciprofloxacin | D002939 | 85721-33-1 | mycoplasma infections | MESH:D009175 | therapeutic | 7596948 | ||
| C0026936 | nitric oxide | D009569 | 10102-43-9 | mycoplasma infections | MESH:D009175 | marker/mechanism | 20179380 | ||
| C0026936 | thiopental | D013874 | 76-75-5 | mycoplasma infections | MESH:D009175 | therapeutic | 10773494 | ||
FDA approved drug and dosage information(Total Drugs:3) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D009175 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D009175 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
| MESH:D009175 | inomax | nitric oxide | 100PPM Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | GAS;INHALATION | Discontinued | None | Yes | No |
FDA labeling changes(Total Drugs:3) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D009175 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D009175 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D009175 | 12/21/2010 | inomax | nitric oxide | Prevention of bronchopulmonary dysplasia | INOmax is not indicated for prevention of BPD in preterm neonates d 34 weeks gestational age.Efficacy for the prevention of BPD in preterm infants was not established in three ldouble-blind, placebo-controlled clinical trials in a total of 2,149 preterm infants Information on clinical trials, adverse reaction | Labeling | B | - | - | - | INO Therapeutics | 2/11/2010 | FALSE' |